Aviva shares: Insanely good! – Financial trends

Aviva has great synergies – focusing on cancer research – and great potential.

Aviva is committed to progress in medicine: as the British insurance company announced a few days ago, it has been selected, along with Socios, as “preferred bidder” for a project in London. The focus is on a planned cancer research and treatment centre, which is to be built in the south of the British capital.

Aviva: London Cancer Center – world-class cancer research

Aviva and Socius want to work closely with the London borough of Sutton and local medical institutes to accelerate the project. The so-called London Cancer Center (LCH) aims to create around 13,000 highly qualified jobs in science, health, education and construction on a five-hectare site.

Charlotte Jones, chief financial officer of the insurance group, said: “Aviva invests heavily in areas vital to the British economy such as housing, green energy and healthcare.” Aviva uses its capital to deliver long-term returns for its customers and support UK growth. Jones continued: “The London Cancer Center will deliver world-class cancer research and support the UK’s ambitions to become a leader in life sciences.”

City area as a biotechnology cluster

To put it in perspective: the London Cancer Center was practically planned as a district. A number of biotechnology companies and healthcare providers are expected to set up shop there in the future. There are also extensive public infrastructure facilities. The most important partner in the project is the London Institute of Cancer Research, which is considered one of the world’s leading cancer research organizations and has been responsible for extraordinary progress in this field in the past.

The LCH is scheduled for completion in the early 1930s.

AVIVA stock chart